Canadian Association of Radiologists Journal
Volume 61, Issue 1 , Pages 13-18 , February 2010

Impact of F-18 Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography on Oncologic Patient Management: First 2 Years' Experience at a Single Canadian Cancer Center

  • Daniel F. Worsley, MD

      Affiliations

    • Division of Nuclear Medicine Vancouver General Hospital, Vancouver, British Columbia, Canada
    • Corresponding Author InformationAddress for correspondence: Daniel F. Worsley, MD, Division of Nuclear Medicine, West 12th Avenue, Vancouver, British Columbia V5Z 1M9, Canada.
    • ,
  • Don C. Wilson, MD

      Affiliations

    • British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • John E. Powe, MD

      Affiliations

    • Division of Nuclear Medicine Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • Francois Benard, MD

      Affiliations

    • British Columbia Cancer Agency, Vancouver, British Columbia, Canada

References 

  1. Canadian Cancer Statistics 2009. Available at: http://www.cancer.ca. Accessed June 1, 2009.
  2. Alessio AM, Kinahan PE, Cheng PM, et al. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am. 2004;42:1017–1032
  3. Beauregard JM, Croteau E, Ahmed N, et al. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT. J Nucl Med. 2009;50:100–107
  4. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153–167
  5. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11:7967–7985
  6. Mankoff DA, Eary JF, Link JM, et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res. 2007;13:3460–3469
  7. Mankoff DA, Link JM, Linden HM, et al. Tumor receptor imaging. J Nucl Med. 2008;49(Suppl 2):49S–63S
  8. Decision memo for positron emission tomography (FDG) for solid tumors (CAG-00181R). 2009; Available at: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=218&. Accessed June 1, 2009.
  9. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155–2161
  10. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008;49:1928–1935
  11. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med. 2007;48:1901–1908
  12. Canadian Agency for Drugs and Technologies in Health. Available at: http://www.cadth.ca/media/healthupdate/Issue8/pet.pdf. Accessed June 1, 2009.
  13. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med. 1998;39:1302–1305
  14. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–895
  15. British Columbia Health Authorities: map of the Provincial Health Authorities. Available at: http://www.health.gov.bc.ca/socsec/provmap.html. Accessed June 1, 2009.
  16. Canadian Institute for Health Information. Medical imaging in Canada 2007. Available at: http://secure.cihi.ca/cihiweb/products/MIT_2007_e.pdf. Accessed June 1, 2009.
  17. Rajendran JG, Greer BE. Expanding role of positron emission tomography in cancer of the uterine cervix. J Natl Compr Canc Netw. 2006;4:463–469
  18. PET scan primer: a guide to the implementation of PET in Ontario. 2008. Available at: http://www.health.gov.on.ca/english/providers/program/ohip/outofcountry/pdf/pet_scan_primer.pdf. Accessed June 1, 2009.
  19. Cleemput I, Camberlin C, Van den Bruel A, et al. Methodology for calculating a country's need for positron emission tomography scanners. Int J Technol Assess Health Care. 2008;24:20–24
  20. Alavi A, Lakhani P, Mavi A, et al. PET: a revolution in medical imaging. Radiol Clin North Am. 2004;42:983–1001
  21. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49:17N–21N
  22. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–385
  23. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48(Suppl 1):78S–88S
  24. Israel O, Kuten A. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med. 2007;48(Suppl 1):28S–35S
  25. Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007;5(Suppl 1):S1–S22quiz S23–2
  26. Wood KA, Hoskin PJ, Saunders MI. Positron emission tomography in oncology: a review. Clin Oncol (R Coll Radiol). 2007;19:237–255
  27. Tucker R, Coel M, Ko J, et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol. 2001;19:2504–2508

PII: S0846-5371(09)00153-3

doi: 10.1016/j.carj.2009.07.005

Canadian Association of Radiologists Journal
Volume 61, Issue 1 , Pages 13-18 , February 2010

Article Tools

* Image Usage & Resolution